Montanova Capital, LLC's Form 4 filing
Benitec Biopharma Inc. (BNTC) · filed Mar 28, 2025
- Accession no.
- 0000899140-25-000479
- Filed
- Mar 28, 2025, 4:51 PM ET
- Trade date
- Mar 26, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $11.7M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Montanova Capital, LLCCIK 0001569064 | Director, 10% Owner |
| Averill Master Fund, Ltd.CIK 0001939329 | Director, 10% Owner |
| Averill Madison Master Fund, Ltd.CIK 0002021243 | Director, 10% Owner |
| Cowen AaronCIK 0001869640 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2025 | Common stock, par value $0.0001 per share | PPurchaseAcquired | +793,800 | $13.00F2 | +$10,319,400 | 8,793,245 | Indirect | |
| Mar 26, 2025 | Common stock, par value $0.0001 per share | PPurchaseAcquired | +106,200 | $13.00F3 | +$1,380,600 | 1,066,764 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Notes are included on Exhibit 99.1.
Referenced by the price of 1 transaction in Table I.
- F3
Notes are included on Exhibit 99.1.
Referenced by the price of 1 transaction in Table I.
Remarks
Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature